Le Lézard
Classified in: Health
Subjects: SVY, ACC

Photocure ASA: Annual Report 2022


OSLO, Norway, April 12, 2023 /PRNewswire/ -- Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2022.

The Board of Directors of Photocure ASA has approved the annual accounts for 2022. The financial statements and annual report for the financial year 2022 are together with the ESG report and auditor's report attached to this notice. The ESEF file for 2022 is also attached.

The documents are enclosed and also made available at the company's website under https://photocure.com/investors-hub/investors-events-and-presentations.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: [email protected]

About Photocure ASA:

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com.

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. This information is subject to the disclosure requirements pursuant to sections 5-12 of the Norwegian Securities Trading Act.

The following files are available for download:

https://mb.cision.com/Main/17498/3749645/1979906.pdf

Release

https://mb.cision.com/Main/17498/3749645/1979907.zip

Photocure ESEF report 2022.zip

https://mb.cision.com/Public/17498/3749645/a1982643aaacf296.pdf

Photocure Annual Report and ESG 2022

 

SOURCE Photocure


These press releases may also interest you

at 16:30
REGULATED INFORMATION Information on the Total Number of Voting Rights and Shares Mont-Saint-Guibert (Belgium), May 28, 2024, 10:30 pm CET / 4:30 pm ET ? In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large...

at 16:18
Dynavax Technologies Corporation , a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June:...

at 16:14
Neurocrine Biosciences, Inc. , today announced that Kevin Gorman, Ph.D., will retire as Chief Executive Officer of Neurocrine on October 11, 2024. Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy...

at 16:10
Exelixis, Inc. today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m. ET / 3:20 p.m. CT / 1:20 p.m. PT in Chicago. To access the webcast...

at 16:10
Revance Therapeutics, Inc. today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief Financial Officer Tobin Schilke is scheduled to present on Tuesday,...

at 16:10
AbCellera today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time). A live audio webcast of the...



News published on and distributed by: